Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years.

Phase 2

Afimmune